Last reviewed · How we verify

ELDECALCITOL — Competitive Intelligence Brief

ELDECALCITOL (ELDECALCITOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed Vitamin D3 receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

ELDECALCITOL (ELDECALCITOL) — Chugai Pharmaceutical Co., Ltd.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ELDECALCITOL TARGET ELDECALCITOL Chugai Pharmaceutical Co., Ltd marketed Vitamin D3 receptor
Infuvite Adult Colecalciferol Novartis marketed Vitamin D Vitamin D3 receptor 2000-01-01
Hectorol DOXERCALCIFEROL Sanofi marketed Vitamin D2 Analog [EPC] Vitamin D3 receptor 1999-01-01
Zemplar PARICALCITOL AbbVie marketed Vitamin D2 Analog [EPC] Vitamin D3 receptor 1998-01-01
Dovonex CALCIPOTRIENE marketed Vitamin D Analog [EPC] Vitamin D3 receptor 1993-01-01
Calcijex CALCITRIOL Esjay Pharma marketed Vitamin D3 Analog [EPC] Vitamin D3 receptor 1978-01-01
Zemplar Zemplar Danderyd Hospital marketed Vitamin D3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ELDECALCITOL — Competitive Intelligence Brief. https://druglandscape.com/ci/eldecalcitol. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: